Swiss Professional Services Stock News

Sika (SWX:SIKA) has just opened five new manufacturing sites across the United States, Argentina, Colombia, Bangladesh, and Tanzania, a move that expands its production footprint and supply chain reach in construction materials. See our latest analysis for Sika. Investors appear to be weighing these new plants against a mixed track record, with the 1-day and 7-day share price returns of 2.9% and 5.1% contrasting with a 1-year total shareholder return decline of about 30%. Recent momentum...

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Zuger Kantonalbank (SWX:ZUGER) has just reported its FY 2025 numbers, with second half total revenue of CHF 160.5 million and net income of CHF 60.2 million, while trailing 12 month revenue came in at CHF 328.5 million and net income reached CHF 131.1 million. The bank has seen total revenue move from CHF 315.1 million on a trailing 12 month basis at the end of the second half of 2024 to CHF 328.5 million by the second half of 2025, alongside a net profit margin of 39.9% and a dividend yield...

Why ARYZTA’s latest guidance is back in focus ARYZTA (SWX:ARYN) drew fresh attention after its 2025 sales and trading statement call on 22 January, alongside new earnings guidance for 2026 that points to revenue growth and improved performance for the year. For you as an investor, that combination of an updated outlook and a recent company communication creates a new reference point for reassessing ARYZTA’s current valuation, recent share price moves and the risks around its 2026 targets. See...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...

Forbo Holding AG has announced that Heinz Hössli will become Chief Financial Officer and Executive Board member on 1 July 2026, succeeding interim CFO Peter Germann, who will retire. This appointment brings in a finance leader with broad international industrial and automation experience, reinforcing Forbo’s leadership bench for its ongoing transformation plans. We’ll now examine how the arrival of an internationally experienced CFO could influence Forbo Holding’s broader investment...

In January 2026, BlackRock and Partners Group launched a first-of-its-kind multi-alternatives separately managed account on the Morgan Stanley wealth platform, giving advisors streamlined access to diversified private equity, private credit, and real assets through three outcome-aligned strategies. This structure is designed to remove common barriers to private market access by consolidating seven evergreen private market funds into a single, operationally simple solution for financial...

Julius Bär Gruppe has reported full-year 2025 results showing net income of CHF 763.7 million versus CHF 1,022.1 million a year earlier, alongside an unchanged proposed ordinary dividend of CHF 2.60 per share and board changes including Juerg Hunziker’s appointment as Vice Chairman. The combination of lower headline profit driven by one-off items and credit write-downs, a steady dividend proposal, and governance refresh underpins an evolving investment story focused on underlying...

It is hard to get excited after looking at Tecan Group's (VTX:TECN) recent performance, when its stock has declined...

Context for Alcon’s recent share performance Alcon (SWX:ALC) has caught investor attention after a period of mixed share performance, with the stock declining over the past month while posting a small gain in the past 3 months. That short term pattern sits alongside a weaker year to date and 1 year total return, prompting some investors to reassess how the eye care group’s current fundamentals and valuation line up with their expectations. See our latest analysis for Alcon. With the share...

Cosmo Pharmaceuticals N.V. recently completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding shares, with Capital Group’s SMALLCAP World Fund, using only existing treasury stock and therefore avoiding dilution for current shareholders. The deal brings a globally recognized institutional investor into Cosmo’s shareholder base while providing additional financial flexibility to support its MedTech AI, dermatology, gastroenterology, and CDMO...

Roche Holding (SWX:ROG) reported positive topline Phase II results for CT-388, its investigational dual GLP-1/GIP receptor agonist for obesity treatment. The trial showed significant and clinically meaningful weight loss outcomes, along with a promising efficacy and safety profile. For Roche, best known for its pharmaceuticals and diagnostics businesses, CT-388 adds focus to its cardiometabolic pipeline at a time when obesity treatments are drawing strong global attention. GLP-1 and GIP...

As the pan-European STOXX Europe 600 Index shows modest gains amid a backdrop of economic optimism and geopolitical concerns, small-cap stocks in Europe are drawing attention for their potential resilience and growth opportunities. In this environment, identifying promising small caps like Spadel requires a focus on solid fundamentals and strategic positioning within their respective industries.

Key Insights R&S Group Holding's estimated fair value is CHF30.92 based on 2 Stage Free Cash Flow to Equity Current...

If you are wondering whether Novartis is still reasonably priced after a strong run, this breakdown is designed to help you weigh what you are paying against what you are getting. The share price recently closed at CHF 116.88, with returns of 0.3% over 7 days, 6.6% over 30 days, 7.7% year to date, 26.6% over 1 year, 74.2% over 3 years and 83.5% over 5 years. These returns sit against a backdrop of continuing interest in large, diversified healthcare groups, as investors look for companies...

Sika recently expanded its global manufacturing network by opening five new plants in the United States, Argentina, Colombia, Bangladesh, and Tanzania to increase production capacity and reinforce its supply chain in key regions. This expansion underscores Sika’s emphasis on being closer to customers in growth markets, enhancing supply reliability and responsiveness across diverse construction material needs. We’ll now examine how this push to boost production capacity in key growth markets...

Adecco Group (SWX:ADEN) is back in focus after launching a global HR and talent consulting platform under its LHH brand. The move puts more weight on advisory services ahead of the upcoming earnings release. See our latest analysis for Adecco Group. The LHH launch comes as Adecco’s CHF23.20 share price sits slightly lower year to date, with a 4.3% 90 day share price return and an 11.5% 1 year total shareholder return, suggesting recent momentum has picked up after a weaker multi year...

Logitech G recently launched the G325 LIGHTSPEED Wireless Gaming Headset, a US$79.99 wireless model offering 24-bit audio, AI-powered noise reduction, LIGHTSPEED connectivity, and seamless switching across PC, consoles, and mobile via dongle and Bluetooth. By combining its proprietary LIGHTSPEED wireless technology with broad device compatibility at a lower price point, Logitech is pushing premium gaming features deeper into the mass-market segment. We’ll now examine how this value-focused...

ams-OSRAM’s ongoing turnaround has involved restructuring and moving away from low-margin LED activities toward automotive and industrial optical semiconductor applications, with management stressing operational improvements and debt reduction as priorities. An interesting angle is how investors and analysts are closely watching AI-driven demand for optical sensors as a potential earnings catalyst, while still highlighting considerable execution and leverage risks. Next, we’ll examine how...

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...

UBS Group (SWX:UBSG) has appointed Nicholas Hinnen as head of premium advisory specialists APAC Switzerland. The newly created role oversees a cross asset advisory team for ultra high and high net worth wealth management clients. The promotion reflects UBS's focus on its Swiss based affluent client segment and tailored advisory services. For you as an investor, this move highlights how UBS is leaning into its core wealth management franchise, where personalised advice and cross asset...

BD and Ypsomed Holding (SWX:YPSN) are expanding their collaboration around a new 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, tailored for Ypsomed’s YpsoMate 5.5 large volume autoinjector platform. See our latest analysis for Ypsomed Holding. Despite the expanded BD partnership around large volume injectors, Ypsomed Holding’s 1 day share price return of 0.16% comes after a softer patch, with a 30 day share price return of 6.71% and a 1 year total shareholder return of 12.36%. This...

HIAG Immobilien Holding (SWX:HIAG) has drawn attention after issuing new guidance indicating that its 2025 consolidated net profit is expected to be 50% to 55% higher than the 2024 figure of CHF 75.2 million. See our latest analysis for HIAG Immobilien Holding. The updated profit outlook arrives after a solid run in HIAG Immobilien Holding's share price, with a 30 day share price return of 4.89%, a 90 day share price return of 13.09% and a 1 year total shareholder return of 45.44%, which...

Comet Holding (SWX:COTN) is back in focus after reporting revenue of CHF 483.201 million and net income of CHF 38.922 million, as investors react to AI driven semiconductor manufacturing demand. See our latest analysis for Comet Holding. At a share price of CHF299.40, Comet Holding has logged a 33.07% 1 month share price return and a 58.41% 3 month share price return. The 1 year total shareholder return of 13.17% points to momentum that has strengthened more recently as investors react to AI...